PharmaTalkRadio

Nanotechnology Keynote Address given by Omid Farokhzad, MD, Professor, Harvard Medical School and Director, Center for Nanomedicine, Brigham and Women's Hospital

Omid Farokhzad is an inventor of more than 145 issued / pending patents. These for the launch of four biotechnology companies: BIND Therapeutics (acquired by Pfizer) Selecta Biosciences, Tarveda Therapeutics (formerly Blend Therapeutics) and Placon Therapeutics (spin-out from Tarveda), which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr Farokhzad has served in various capacities on the Board of Directors and the Scientific Advisory Board of these companies. 

In his lecture, Dr Farokhzad will be focusing on the emerging understanding of the nano-bio interactions and its implications for developing safer and more effective therapeutic and diagnostic modalities. Nanotechnology enabled drug delivery approaches for predictive and personalized medicines will be discussed with emphasis on the lessons that been learned during their bench-to- bedside translation. 

Omid Farokhzad, MD 

Professor, Harvard Medical School and Director Center for Nanomedicine, Brigham and Women's Hospital 

This talk was given at the 7rth annual Partnership Opportunities for Drug Delivery (PODD) Meeting in 2017.

Panel: Utilizing a Device Platform Technology across Multiple Therapeutic Categories

Most pharma and biotech companies realize the need and benefit of having a platform device technology. The challenge then becomes figuring out how to utilize the device to deliver different types of drugs for various indications such as rheumatoid arthritis, cancer, and rare diseases.

Moderator: Paul Jansen

Former Associate VP Sanofi and Board Member and Senior Advisor, Haselmeier

Panelists: Donna French, PhD

VP Drug Delivery and Device Development, MedImmune

Michael Graffeo, MBA

VP Business Development, Drug Delivery Insulet

Rajan Patel

CEO, io Life science

Srini Sridharan, PhD

Group Director, Materials Science and Engineering, BMS

The Keynote was given at Partnerships Opportunities in Drug Delivery 2017 by

Lars Rebein Sorensen

Former President and CEO, Novo Nordisk

with 

Barbara Lueckel, PhD

Global Business Development Director Roche Partnering Innovation, Roche

The expert panel of scientific leaders from industry will discuss current formulation and delivery challenges for therapeutic areas (ophthalmology, immunology, oncology infectious disease, and neurodegenerative area disorders). Each panelist will address a specific disease area and discuss the role of drug delivery in the treatment of disease. The panel will also cover currently available delivery technologies and where improvement is needed.

Moderator: Ann Daugherty, PhD

Senior Manager, Drug Delivery, Genentech

Panelists: Marianne Ashford, PhD

Senior Principal Scientist, Pharmaceutical Sciences, AstraZeneca

Advait Badkar, PhD

Senior Director Novel Delivery Technologies, Bio Therapeutics, Pfizer

Marian Gindy, PhD

Executive Director Pharmaceutical Sciences, Merck

Kapil Gupta, PhD

Associate Director, Protein Pharmaceutical Development, Biogen

Evan Thackaberry, PhD, DABT

Headm Preclinical Development, Ra Pharmaceuticals

This talk was given on Day 2 of the Partnership Opportunities in Drug Delivery (PODD) 2017 Meeting.

The expert panel will address the scientific and business challenges and opportunities in this space. Panelists will discuss the difficult nature of providing therapies for diseases of the CNS, covering both device and chemistry-enabled technologies. They will also address questions such as: 

Can devices take us where chemistry has not?What advances being made in the field of chemis conjugation technologies?Why is intrathecal, intracerebroventricular and intraparenchymal delivery relevant for CNS and other therapeutic categories?

Finally the panel will talk about lessons learned, particularly with regard to scientific vs. business rationale.

Introduction by:

PJ Anand

Founder President and CEO, Lifesciences

Moderator: Lisa Shafer, PhD

Senior Director New Devices and Bioelectronic Technologies Teva Pharmaceuticals

Panelists: Dan Abrams, MD

CEO, Cerebral Therapeutics, LLC 

Krystof Bankiewicz, MD, PhD

Director, Interventional Neuro Center UCSF

Mikhail "Misha" Papisov, PhD

Associate Professor Harvard Medical School and Massachusetts General Hospital

Lamya Shihabuddin, PhD

R&D Cluster Head Neuro Rare Diseases, Sanofi R&D  

This Discussion took place on Day 2 of the Partnership Opportunities in Drug Delivery (PODD) 2017 Meeting.

Drug Delivery Needs in Oncology

Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in technologies that facilitate subcutaneous administration and potentially enable drug administration in the home setting. 

Led by: Beate Bittner, PhD

 Portfolio Strategy Director, Roche 

Panelists: Panel: H Janice Adkins, MBA

Associate Director Marketing, BD Medical The exp Pharmaceutical Systems, North America EMEA

Ulrich Bruggemann

Head Academics and Innovation, Global Medical Devices of the Development, Sanofi US

Shawn Davis, PhD

Director, Technology Strategy and Innovation, Amgen

Declan Reilly

Section Head, Device Engineering, Device Development PTDE-D, Roche

Andrew J Yee, MD Medical Oncologist, Massachusetts General Hospital Cancer Center 

This presentation took place at the 7th Annual Partnership Opportunities in Drug Delivery (PODD) 2017.

Track 2: Clinical Operations for IO Trials

This section is designed for clinical trial operation executives who want to learn what it takes to execute an IO clinical trial. This is an

excellent opportunity to walk through the building blocks of IO clinical trial operations and discuss pitfalls and lessons learned.

Plenary Chair:

Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck

 

This discussion was presented at the 2018 Immuno-Oncology 360° Meeting.

Building Blocks of IO Trials: This talk will consist of 7 perspectives that identify operational aspects of IO trials, including a patient

perspective, site management, 3rd party component, clinical supply chain, a PI perspective, data management and project

management. The collaborative talk concludes with a panel discussion and Q&A.

 

This Discussion was presented at the 2018 Immuno-Oncology 360° Meeting.

Endpoints News Industry Report on IO Collaborations and Trends

In this episode of Pharma Talk Radio, John Carroll, Editor-in-Chief of Endpoints News, reviewed the build up of the immuno-oncology space over the past few years at the IO360° conference that took place February 2018. Mr Carroll discussed the impact the large amount of money and the extraordinary numbers that have been invested in the space, have had on collaborations. He also shed light on the natural limitations and boundaries that are going to impact IO R&D, along with exploring China as an upcoming major player in the IO space.

About John Carroll:

John Carroll is a biotech analyst with 38 years of prize-winning experience in journalism. For more information visit: https://endpts.com/

This talk was given at Day 2 of Immuno-Oncology 360° meeting  in 2018.

Save the Date: The 5th annual Immuno-Oncology 360° program will take place February 6-8, 2019 in NYC. For more information visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

Mobile Podcast Series #2

CTTI Findings are in from their Mobile Clinical Trials Program: Recommendations on Novel Endpoints

CTTI's Mobile in Clinical Trials program was launched three years ago to propose recommendations that clarify the pathway for developing novel endpoints for use in clinical trials from data generated using mobile technology. Jennifer Goldsack shares recommendations and insights from their findings on:

Developing an internal process for identifying endpointsStrategies for reducing friction throughout the processExecuting the processThe science required to validate an endpointA suite of tools developed in the process to help facilitate implementation

The next Mobile in Clinical Trials conference is September 24 in Boston. Mobile is the annual update on not only the latest progress in applying mobile/digital tools to clinical trials, but how and when to do this and for what benefit. 

Speaker: Jennifer Goldsack, MChem, MA, MBA, CPHQ, Clinical Project Manager, CTTI

Producer: Valerie Bowling, Executive Director, Mobile in Clinical Trials